AAV Gene Therapy Analytical
Development and Quality Control
Specialized gene therapy analytical methods and QC consulting: from ATP design through ICH-compliant method validation, potency assay development, and AAV vector characterization for IND, BLA, and commercial submissions.
Product Quality & Compliance Excellence
Commitment to
Deliver Product Quality
DES Pharma provides comprehensive analytical and quality control support across all stages of drug development. From method development to routine testing and regulatory compliance, we ensure your AAV gene therapy and biologic products meet rigorous standards for safety, efficacy, and quality.
Our analytical team has deep experience in viral vector characterization, including the specialized assays required for gene therapy: potency assays, empty/full capsid analytics, residual DNA and host cell protein testing, and ICH-compliant method lifecycle management.
AAV Gene Therapy Characterization Methods
Specialized analytical capabilities for adeno-associated virus vector quantification and quality assessmentThese AAV characterization methods include empty/full capsid ratio analysis, vector genome titer (ddPCR, qPCR), and residual DNA testing. Our analytical consultants develop fit-for-purpose methods that meet FDA and EMA expectations for gene therapy IND and BLA submissions per ICH Q2(R2) and ICH Q14.
Guiding Analytical Strategy Through Data
Our AD & QC Frameworks
for Gene Therapy
We build structured frameworks that uphold the core principles of analytical development and quality control, calibrated for the unique complexity of AAV and viral vector products.
Analytical Development (AD)
High Structure, High ROI
Analytical Development provides scientific expertise to support key decision points related to AAV gene therapy product safety and efficacy across all phases of development.
- Develop accurate, fit-for-purpose analytical methods to measure critical quality attributes (CQAs) for identity, safety, potency, and purity
- Define the Analytical Target Profile (ATP) aligned with the Target Product Profile (TPP), including gene therapy-specific CQAs
- Leverage AAV characterization data to enhance product knowledge and optimize methods with innovative technologies
- Establish product degradation profiles and identify the pathways behind them for vector stability
- Develop specifications aligned with ICH Q6B and gene therapy guidance from FDA/CBER and EMA
- Analytical lifecycle management per ICH Q14 and USP framework
Quality Control (QC)
Driving Data-Backed Decisions
Quality Control ensures AAV gene therapy products are consistently safe, effective, and high-quality by establishing a clear testing system aligned with global regulations.
- Ensure compliance of test panels for product release, routine testing, and stability studies across the viral vector product lifecycle
- Monitor analytical method performance to maintain consistent product quality, patient safety, and potency
- Meet regulatory requirements for data integrity (21 CFR Part 11) and ICH Q14 standards
- Risk-based approach to confirm testing methods are reliable across all development phases
- Continuous monitoring and improvement processes to ensure trustworthy data for regulatory approvals
- OOS investigation management and CAPA implementation for analytical deviations
AAV-Specific Analytical Methods Reference
Critical Quality Attributes
& Testing Methods
| CQA / Attribute | Recommended Method(s) | Regulatory Reference | Type |
|---|---|---|---|
| Vector Genome Titer | ddPCR, qPCR (ITR or transgene-based) | FDA CBER Guidance 2020; ICH Q2(R2) | CQA |
| Empty/Full Capsid Ratio | AUC, AEX-HPLC, TEM, ELISA | FDA Gene Therapy Guidance 2021 | CQA |
| Capsid Titer (Physical Particles) | ELISA (capsid), MALS, DLS | USP <788>; ICH Q6B | CQA |
| Potency (Transduction) | In vitro transduction assay, luciferase reporter, FACS | ICH Q6B; FDA Potency Guidance | CQA |
| Purity: HCP | Host Cell Protein ELISA (process-specific) | ICH Q6B; USP <1132> | Purity |
| Purity: Residual DNA | qPCR (host cell DNA), ThunderBird assay | FDA 21 CFR 610; ICH Q5A | Purity |
| Identity | SDS-PAGE / Western Blot, VP1/VP2/VP3 ratio | ICH Q6B; USP <1084> | Identity |
| Sterility & Mycoplasma | USP <71> sterility; PCR mycoplasma | 21 CFR 610.12; ICH Q5A | Safety |
| Adventitious Agents | Broad-range PCR, cell-based assays, in-vivo testing | ICH Q5A(R2); FDA CBER Guidance | Safety |
Gene Therapy Analytical Expertise Deep Expertise in AAV Vector Characterization
Gene therapy analytical development requires more than standard biologic methods. AAV vectors present unique characterization challenges: quantifying both physical and functional particles, assessing capsid integrity and empty/full ratio, and developing potency assays that are clinically relevant, reproducible, and transfer-ready.
Our team has built and validated AAV-specific analytical panels across serotypes, supporting programs from early pre-clinical qualification through ICH-compliant BLA method validation packages. We align every method to the Analytical Target Profile (ATP) and support regulatory submissions to FDA CBER and EMA using current guidelines for gene therapy products.
From selecting the right ddPCR approach for vector genome titer to developing a robust cell-based transduction potency assay that passes ICH Q2(R2) validation, DES Pharma delivers analytical solutions that hold up through tech transfer and regulatory scrutiny.
Potency Assay Development & Validation
Cell-based transduction assays, reporter systems, FACS-based quantification: designed for robustness, transferability, and ICH Q2(R2) / ICH Q6B compliance
Empty/Full Capsid Ratio Analytics
AUC, AEX-HPLC, and TEM methods for capsid occupancy: critical CQA for AAV efficacy and safety per FDA CBER gene therapy guidance
Method Lifecycle Management
ATP-driven approach aligned with ICH Q14 and USP: from development through routine QC, tech transfer, and post-approval change management
Specification Development & Justification
Science- and risk-based specification setting for release and stability, with regulatory justification documents aligned with ICH Q6B and FDA expectations
Analytical Method Tech Transfer
Structured transfer protocols, acceptance criteria, and comparative testing packages for CDMO and QC laboratory transitions
Full-Spectrum Analytical Services
AD & QC Services for
Gene Therapy Programs
Comprehensive analytical and quality control consulting across
the entire AAV gene therapy development lifecycle.
Analytical Development (AD) Services
- Laboratory space design and equipment commissioning
- Selection of fit-for-purpose analytical technologies for AAV
- Method design for starting/raw materials, drug substance, drug product, and process intermediates
- Establish product degradation profile and identify the pathways behind it
- Correlative analysis of analytical and stability data with product performance
- AAV-specific specification development (vector genome titer, capsid titer, potency, purity)
- Generate data sets and analytical summaries for IND/BLA filings
- Analytical lifecycle management (ICH Q14 / USP)
- Reference standard program development and qualification
Quality Control (QC) Services
- Routine testing: identity, safety, potency, and purity for AAV release
- Product characterization (extended characterization panel)
- Method validation per ICH Q2(R2) and ICH Q14
- Laboratory operation requirements for GLP and GMP testing
- Performance monitoring and trending of analytical methods
- Generate protocols and reports for use in regulatory filings
-
Analytical method tech transfer
(development → QC → CDMO) - Laboratory audit support and data integrity assessments
- Justification of Specifications documentation
- OOS investigation and CAPA management
Get Started Advance Your AAV Analytical Program with Confidence
Build robust, regulatory-ready analytical methods for your gene therapy product today.